Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia.

@article{Ranganathan2015DecitabinePE,
  title={Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia.},
  author={Parvathi Ranganathan and Xueyan Yu and Ramasamy Santhanam and Jessica Hofstetter and Alison R. Walker and Katherine J. Walsh and Bhavana Bhatnagar and Rebecca B. Klisovic and Sumithira Vasu and Mitch A Phelps and Steven Michael Devine and Sharon Shacham and Michael G. Kauffman and Guido Marcucci and William G Blum and Ramiro Garzon},
  journal={Blood},
  year={2015},
  volume={125 17},
  pages={2689-92}
}
The prognosis of acute myeloid leukemia (AML) is poor, highlighting the need for novel treatments. Hypomethylating agents, including decitabine are used to treat elderly AML patients with relative success. Targeting nuclear export receptor (exportin 1 [XPO1]) is a novel approach to restore tumor suppressor (TS) function in AML. Here, we show that sequential treatment of AML blasts with decitabine followed by selinexor (XPO1 inhibitor) enhances the antileukemic effects of selinexor. These… CONTINUE READING